Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vimseltinib - Deciphera Pharmaceuticals

Next Previous
Drug Profile

Vimseltinib - Deciphera Pharmaceuticals

Alternative Names: DCC 3014; DP-6865; ROMVIMZA

Latest Information Update: 25 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Deciphera Pharmaceuticals; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Giant cell tumour of tendon sheath
  • Phase II Graft-versus-host disease
  • Phase I/II Solid tumours
  • No development reported Sarcoma

Most Recent Events

  • 14 Feb 2025 Registered for Giant cell tumour of tendon sheath (Inoperable/Unresectable, Late-stage disease) in USA (PO)
  • 14 Feb 2025 Deciphera Pharmaceuticals plans to launch vimseltinib (ROMVIMZA) in the US
  • 23 Jan 2025 Preregistration for Giant cell tumour of tendon sheath (Inoperable/Unresectable, Late-stage disease) in Hong Kong, Australia (PO), prior to January 2025 (Ono Pharmaceutical pipeline, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top